OKUR
OnKure Therapeutics, Inc.NASDAQHealthcare$4.29+1.40%ClosedMarket Cap: $58.7M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.05
P/S
0.00
EV/EBITDA
-0.02
DCF Value
$4.23
FCF Yield
-87.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-81.7%
ROA
-95.8%
ROIC
-110.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-13.5M | $-0.99 |
| FY 2025 | $0.00 | $-59.5M | $-4.40 |
| Q3 2025 | $0.00 | $-14.7M | $-1.09 |
| Q2 2025 | $0.00 | $-15.4M | $-1.14 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$35.00
Target (Median)
$35.00
Target Range
$35.00 - $35.00
0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-03-16HC Wainwright & Co.Buy
2025-08-26Trading Activity
Insider Trades
View AllAgresta Samuelofficer: Chief Medical Officer
SellFri Apr 03
Hartley Dylanofficer: Chief Scientific Officer
SellFri Apr 03
Leverone Jason A.officer: Chief Financial Officer
SellFri Apr 03
Saccomano Nicholas Adirector, officer: President and CEO
SellFri Apr 03
Ratcliffe Liamdirector
SellWed Apr 01
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.46
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.